Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-52019.79%
operating margin TTM
-34632.29%
revenue TTM
27.12 Million
revenue per share TTM
2.4$
valuation ratios | |
|---|---|
| pe ratio | -2.38 |
| peg ratio | 0.06 |
| price to book ratio | 2.59 |
| price to sales ratio | 997.06 |
| enterprise value multiple | -3.23 |
| price fair value | 2.59 |
profitability ratios | |
|---|---|
| gross profit margin | -15.1% |
| operating profit margin | -34632.29% |
| pretax profit margin | -51942.19% |
| net profit margin | -52019.79% |
| return on assets | -79.84% |
| return on equity | -88.43% |
| return on capital employed | -56.77% |
liquidity ratios | |
|---|---|
| current ratio | 14.28 |
| quick ratio | 14.28 |
| cash ratio | 3.38 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 782.85 |
| cash conversion cycle | -782.85 |
| receivables turnover | 0.00 |
| payables turnover | 0.47 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | 0.00 |
| cash flow to debt ratio | 0.00 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.73 |
| cash per share | 7.97 |
| operating cash flow per share | -3.73 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | 0.00 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time Avalo Therapeutics, Inc. (NASDAQ:AVTX) reported earnings?
Avalo Therapeutics, Inc. (AVTX) published its most recent earnings results on 06-11-2025.
What is Avalo Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Avalo Therapeutics, Inc. (NASDAQ:AVTX)'s trailing twelve months ROE is -88.43%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Avalo Therapeutics, Inc. (AVTX) currently has a ROA of -79.84%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did AVTX's net profit margin stand at?
AVTX reported a profit margin of -52019.79% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is AVTX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 14.28 in the most recent quarter. The quick ratio stood at 14.28, with a Debt/Eq ratio of 0.00.